Alkermes
Alkermes plc, a leading biopharmaceutical company headquartered in Ireland, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established a strong presence in the global healthcare market, with significant operations in the United States and Europe. The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it as a key player in the biopharmaceutical industry, with notable achievements in advancing patient care through its proprietary formulations. With a focus on scientific excellence and patient-centric solutions, Alkermes continues to drive innovation and improve outcomes for individuals affected by serious mental health conditions.
DitchCarbon Score
How does Alkermes's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkermes's score of 26 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alkermes's reported carbon emissions
In 2023, Alkermes reported total greenhouse gas emissions of approximately 32,480,000 kg CO2e, comprising 15,753,000 kg CO2e from Scope 1 and 16,726,000 kg CO2e from Scope 2 emissions. This represents a significant commitment to transparency in their climate impact, although no specific reduction targets have been disclosed. Over the years, Alkermes has shown a gradual decrease in emissions per employee, with figures dropping from 107 kg CO2e in 2015 to 250 kg CO2e in 2023. The company has also reported emissions per floor area and per million dollars of revenue, indicating a focus on efficiency in their operations. Despite the lack of formal reduction targets or initiatives, Alkermes continues to monitor and report its emissions, reflecting an awareness of its environmental responsibilities. The company’s headquarters is located in Ireland (IE), and it operates within the global pharmaceutical industry, which is increasingly prioritising sustainability and climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 16,997,000 | 00,000,000 |
| Scope 2 | 16,813,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alkermes is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
